New Acquirers Highlight Medtech M&A; Volatility May Mean Wait Until Next Year For IPOs

article image
ARTICLE SUMMARY:

One of the biggest concerns of entrepreneurs and investors emerging from the rash of recent large medtech consolidation deals is that this trend further thins out an already relatively small group of potential strategic acquirers.

Our regular quarterly review of the US medtech M&A and IPO markets shows that, through the third quarter of this year, those concerns appear to be unfounded when it comes to acquisitions.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: